Welcome to our dedicated page for TELA Bio SEC filings (Ticker: TELA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TELA Bio, Inc. filings document a commercial-stage medical technology business centered on soft-tissue reconstruction and the OviTex product portfolio for hernia repair and abdominal wall reconstruction. Form 8-K reports cover operating and financial results, revenue updates, Regulation FD disclosures, material agreements, debt and equity capital structure, and other material events tied to the company's medical technology operations.
Proxy materials and governance-related 8-Ks record board composition, director appointments and resignations, executive compensation matters, stockholder meeting proposals, inducement and equity-award practices, and Nasdaq listing-compliance disclosures for TELA common stock listed on the Nasdaq Global Market.
TELA Bio, Inc. reports that Chief Executive Officer Heather C. Getz received new equity awards on August 3, 2026. She was granted 500,000 restricted stock units of common stock, increasing her holdings to 505,000 shares. She also received options for 1,365,000 shares at a $0.74 exercise price and 1,005,000 shares at $0.90, both expiring August 3, 2036. The RSUs vest in four equal annual installments beginning August 3, 2027, and each option vests 25% on that date with the remaining 75% vesting monthly over 36 months, subject to continued service.
TELA Bio, Inc. director and Chief Executive Officer Heather C. Getz filed an initial statement of beneficial ownership, reporting 5000.0000 shares of Common Stock held directly as of 2026-08-03. The filing also references an Exhibit 24 Power of Attorney authorizing certain SEC filing actions.
TELA Bio, Inc. made a leadership change on August 3, 2026, when the board determined that Antony Koblish would no longer serve as chief executive officer and principal executive officer and he resigned from the board, with his departure treated as a termination without cause and a separation agreement to be finalized and disclosed later.
The board appointed Heather Getz as chief executive officer, principal executive officer and a Class II director, and entered into an employment agreement providing a $650,000 base salary, a target annual bonus equal to 100% of salary, severance of 12 months salary and benefits if terminated without Cause or for Good Reason, enhanced to 18 months salary, 150% of target bonus and accelerated equity vesting during a Change of Control Period. As inducement equity, she received options for 1,365,000 shares at market price, premium options for 1,005,000 shares at the higher of $0.90 or a 15% premium, and 500,000 RSUs, plus potential top-up grants so that her Initial and Top-Up Grants equal 5% of outstanding shares after future equity financings.
Plovanic William J. reported acquisition or exercise transactions in this Form 4 filing.
TELA Bio, Inc. director William J. Plovanic received a grant of 20,930 shares of common stock, valued at $0.785 per share, as compensation. The shares were issued in lieu of cash under the company’s Amended and Restated Non-Employee Director Compensation Policy and are fully vested, bringing his direct holdings to 44,530 shares.
Capper Joseph H reported acquisition or exercise transactions in this Form 4 filing.
TELA Bio, Inc. director Joseph H. Capper received a grant of 6,227 shares of common stock on 2026-07-15. The shares were issued in lieu of cash compensation under the company’s Amended and Restated Non-Employee Director Compensation Policy and are fully vested. Following this grant, Capper directly owns 29,827 shares of TELA Bio common stock.
TELA Bio director Betty Jo Rocchio received new equity awards. She was granted 11,675 restricted stock units of common stock, increasing her direct common stock holdings to 23,600 shares after the award. These units vest on the earlier of June 9, 2027, the next annual stockholder meeting, or a Change in Control, subject to her continued service.
She also received a stock option covering 17,335 shares of common stock at an exercise price of $0.935 per share, expiring on June 9, 2036. This option vests on the same schedule and service conditions as the restricted stock units.
TELA Bio, Inc. director Joseph H. Capper reported receiving new equity awards in the form of common stock and stock options as compensation. On June 9, 2026 he was granted 11,675 and 11,925 restricted stock units, and options for 17,335 and 17,550 shares at an exercise price of $0.935 per share expiring on June 9, 2036.
The restricted stock units vest over time, either in three equal annual installments beginning on June 9, 2027 or on the earlier of June 9, 2027, the next annual stockholder meeting, or a Change in Control under the company’s 2019 equity plan, in each case requiring continued service. Following these grants, one line shows 23,600 common shares and another 11,925 common shares held directly.
TELA Bio, Inc. director Joseph H. Capper has filed an initial statement of beneficial ownership as an insider. This Form 3 does not report any insider purchases, sales, option exercises, gifts, or other equity transactions, reflecting only his new status as a reporting person.
TELA Bio director William J. Plovanic received new equity awards as part of his compensation. He was granted 11,675 shares of common stock and a stock option for 17,335 shares at an exercise price of $0.935 per share.
The stock units and the option both vest on the earlier of June 9, 2027, the next annual meeting of stockholders, or a Change in Control under TELA Bio’s Amended and Restated 2019 Equity Incentive Plan, in each case subject to his continued service. Following the grant, he directly owns 23,600 common shares and holds the new option for 17,335 underlying shares.
TELA Bio, Inc. director Guido J. Neels filed an initial insider ownership report on Form 3. This filing establishes his status as a director and is a baseline regulatory disclosure. The data provided shows no reported purchases, sales, or other transactions in TELA Bio securities.